top of page
Backgrounds.jpg

The voice of Colville and northeastern Washington since 1896

|

September 15, 2026

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Dyne Therapeutics, Inc. - Common Stock (NQ:DYN)

15.22 -0.60 (-3.79%)
Delayed Quote Updated: 2:44 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Dyne Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Dyne Therapeutics Inc. (NASDAQ: DYN) Leading the Way in Thursday Trading Based on Percentage Gain
Via Investor Brand Network
News headline image
Why Mobileye Global Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Shares of Mobileye Global Inc. (NASDAQ: MBLY) fell sharply during Thursday’s session after the company issued preliminary FY23 financial results and initial 2024 guidance.< 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Shares of Dyne Therapeutics Fell This Week ↗
Insiders sold more than 15,000 shares of company stock on Tuesday. 
Via The Motley Fool
News headline image
Dow Surges 200 Points; US Services PMI Edges Higher In December ↗
U.S. stocks traded mostly higher midway through trading, with the Dow Jones index gaining around 200 points on Thursday. The Dow traded up 0.55% to 37,635.05 while the NASDAQ rose 0.05% to 14,599.10.... 
Via Benzinga
Topics Stocks
News headline image
Lamb Weston Posts Upbeat Results, Joins Omega Therapeutics, Allstate And Other Big Stocks Moving Higher On Thursday ↗
U.S. stocks traded mostly higher, with the Dow Jones index gaining around 150 points on Thursday. Shares of Lamb Weston Holdings, Inc. (NYSE: LW) rose during Thursday’s session following... 
Via Benzinga
Topics Stocks
News headline image
Cal-Maine Posts Downbeat Q2 Results, Joins Dyne Therapeutics, OPKO Health And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
U.S. stock futures were higher this morning, with the Dow Jones futures gaining around 50 points on Thursday. 
Via Benzinga
Topics Stocks
News headline image
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why SoFi Technologies Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Shares of SoFi Technologies, Inc. (NASDAQ: SOFI) fell sharply during Wednesday’s session after Keefe, Bruyette & Woods downgraded rating on the stock. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
TDCX Receives Preliminary Non-binding Proposal Letter, Joins Pure Storage, Dyne Therapeutics And Other Big Stocks Moving Higher On Wednesday ↗
U.S. stocks traded lower, with the Nasdaq Composite falling around 150 points on Wednesday. Shares of TDCX Inc. (NYSE: TDCX) rose sharply during Wednesday’s session after it disclosed receiving a... 
Via Benzinga
Topics Stocks
News headline image
Why Is Pinstripes (PNST) Stock Down 12% Today? ↗
Pinstripes stock is sliding lower on Wednesday as shares of PNST give up some of the gains they saw during their public debut yesterday. 
Via InvestorPlace
News headline image
Why Is Flex (FLEX) Stock Moving Today? ↗
Flex stock is on the move Wednesday after the company completed its spinoff of Nextracker by distributing its stake to holders of its stock. 
Via InvestorPlace
News headline image
Why Is Trinity Place (TPHS) Stock Up 97% Today? ↗
Trinity Place stock is up on Wednesday as investors in TPHS react to a new forbearance agreement update with heavy trading of the shares. 
Via InvestorPlace
News headline image
Why Is Dyne Therapeutics (DYN) Stock Up 39% Today? ↗
Dyne Therapeutics stock is rising higher on Wednesday as investors in DYN react to positive clinical trial news from the company. 
Via InvestorPlace
News headline image
Why Is Rare Muscle Disease-Focused Dyne Therapeutics Stock Soaring Today? ↗
Dyne Therapeutics Inc (NASDAQ: DYN) released initial clinical data from its ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1) and its DELIVER trial of DYNE-251 in patients with... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
It's time to dive into the biggest pre-market stock movers with all of the latest coverage worth reading about on Wednesday morning! 
Via InvestorPlace
News headline image
Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrating Promise of the FORCE™ Platform in Developing Therapeutics for Rare Muscle Diseases
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics to Host Virtual Event Tomorrow, January 3 at 8:00 AM ET, to Present Initial Clinical Data from ACHIEVE and DELIVER Trials
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
3 of the Best Cheap Stocks Under $20 to Buy Now: November Edition ↗
After dropping to 52-week lows, the markets have been rallying, sending traders and investors are looking for cheap stocks under $20. 
Via InvestorPlace
News headline image
Dyne Therapeutics to Present at November Investor Conferences
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Reports Third Quarter 2023 Financial Results and Provides Update on Significant Progress for ACHIEVE and DELIVER Trials and Upcoming Clinical Milestones
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics to Present at October Investor Conferences
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Receives FDA Orphan Drug Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics to Present at Jefferies Healthcare Conference
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-101
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics’ Preclinical Data Demonstrating FORCE™ Platform Delivery to CNS Featured in Oral Presentation at ASGCT Annual Meeting
From Dyne Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
bottom of page